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The claim that postmenopausal hormone replacement
therapy (HRT) reduces coronary heart disease (CHD) risk
by 50% has until recently been a mantra in female health
care and, to a lesser extent, in preventive cardiology [1].
This belief originated in the 1960s and is based on the
logic that if the menopause causes CHD (a dubious
proposal at best) then oestrogen replacement should
prevent the disease. Plasma lipoprotein levels were an
aspect of metabolism that was at the core of cardiovascular
research at that time, and the changes in response to
oestrogen were encouraging [2].
A low incidence of CHD was subsequently shown in
observational (nonrandomized) studies of HRT users [3]. This
association was strengthened by the antiatherosclerotic
effect of oestrogen demonstrated in fat-fed animals [4],
which was consistent with the identification of this steroid as
a powerful vasoactive agent.
Administration of HRT through skin patches has become a
common treatment option in postmenopausal women [5],
resonating with the late 20th century distrust of ‘pills’. By
providing relatively stable blood hormone levels, it was
expected to reduce side effects and improve compliance.
The major disadvantages, aside from cost, are that patches
may fall off or induce skin reactions. These problems have
been minimized by advances such as ‘matrix’ patches that
incorporate the steroid in the adhesive layer of the patch.
Transdermal HRT is as effective as oral HRT in relieving
climacteric symptoms, such as hot flushes, and has
comparable effects on bone metabolism and bone density.
Some women prefer patches and others prefer pills, and with
such a complex and multisystem condition as the menopause
it was always unlikely that any one therapy would emerge as
a clear favourite.
Transdermal and oral HRT differ in their impact on some
CHD risk factors (Table 1). The long-standing view that oral
HRT prevents CHD has been strongly challenged by recent
randomized controlled trials [6]. Whereas a few years ago
the question of interest was whether transdermal HRT could
match the cardiovascular benefits of oral HRT, we have now
entered a new phase in which the transdermal route might
even be preferable.
Commentary
Do we need clinical trials to test the ability of transdermal HRT to
prevent coronary heart disease?
David Crook
Department of Cardiovascular Biochemistry, St Bartholomew’s and the Royal London School of Dentistry and Medicine, London, UK
Correspondence: David Crook, e-mail: dcrook@mac.com
Published online: 10 September 2001
Curr Control Trials Cardiovasc Med 2001, 2:211-214
© 2001 BioMed Central Ltd (Print ISSN 1468-6708; Online 1468-6694)
Abstract
Postmenopausal hormone replacement therapy (HRT) with oral oestrogen was predicted to reduce
coronary heart disease (CHD) risk by 50%. Randomized controlled trials show no such benefit,
however, pointing instead to an initial increase in CHD events. Although the cardiovascular effects of
transdermal HRT are largely unknown, improvements in arterial function are maintained when
oestrogen is administered transdermally. Transdermal HRT also avoids the increased plasma levels of
C-reactive protein (CRP) that are seen with oral HRT. However, the clinical significance of this general
reduction in hepatic over-synthesis of plasma proteins is difficult to assess. Nevertheless, the available
evidence on transdermal HRT appears to justify a formal clinical trial.
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Oral hormone replacement therapy and
coronary heart disease
When oestrogen is given orally the liver reacts to the rapid
increase or ‘bolus’ of hormone emerging in the hepatic portal
vein by attempting to deactivate this seemingly alien material.
Relatively large steroid doses are needed to overcome this
‘first-pass’ effect in order to ensure sustained and clinically
relevant plasma hormone levels. One consequence of this
overdosing is a dramatic increase in hepatic synthesis (and
hence plasma levels) of many proteins, including those that
are involved in haemostasis and blood pressure regulation [7].
Transdermal delivery of oestrogen was developed in part to
avoid this over-synthesis, although a certain amount of
hepatic stimulation may be desirable. For instance, oral
oestrogen induces hepatic synthesis of apolipoprotein A-I
and so increases plasma levels of high-density lipoproteins
(HDLs) – a change that is often considered pivotal to the
perceived cardiovascular benefit of HRT. The possibility that
the transdermal route may have advantages or disadvantages
over oral HRT in CHD prevention could form the basis of a
clinical trial.
Transdermal hormone replacement therapy
and coronary heart disease
In the first randomized controlled trial of the effects of
transdermal HRT on CHD end-points, the Papworth HRT
Atherosclerosis Study, 255 women with angiographically
defined CHD were randomly assigned to receive placebo or
transdermal HRT [8]. That study was terminated prematurely
because of a higher incidence of myocardial infarction, stroke
and venous thromboembolism in the transdermal HRT group
– a similar pattern to that encountered in recent trials of oral
therapy [6]. There are obvious concerns that this trial was
underpowered, a limitation that was exacerbated by a 40%
dropout rate in HRT users. Some would argue that these
results are not relevant to the average HRT user, but it should
be remembered that the consensus has always been that
HRT is especially beneficial in CHD patients [9].
Although transdermal oestradiol was no better than placebo
in preventing atherosclerosis in fat-fed rabbits [10], the
possibility of clinical benefit of transdermal HRT has been
raised in a case–control study conducted by a manufacturer
of the skin patches [11]. The health records of 164,769
women in UK general practices were used to assemble an
adjusted odds ratio for myocardial infarction of 0.75 (95%
confidence interval 0.47–1.21) in women currently or
recently using transdermal HRT, as compared with nonusers.
The limitation of such an observational study is that women
often choose HRT of their own volition, which leads to health
and health care differences between HRT users and control
individuals. Observational epidemiological studies cannot
adjust adequately for baseline differences in socioeconomic
status and other CHD risk factors. Even conventional risk
factors such as hypertension and dyslipidaemia are poorly
quantified in such surveys.
The coronary heart disease risk profile of
transdermal hormone replacement therapy
The evidence for transdermal HRT is often inconclusive.
Research is frequently contaminated by the concomitant use
of different types and doses of progestins to prevent
oestrogen-induced endometrial hyperplasia and cancer, with
the route of progestin administration being less of an issue.
Progestins can exhibit androgenic characteristics and in
particular can reduce oestrogen-induced rises in plasma
levels both of HDLs and of fasting triglycerides. This
antagonism is, in theory, both undesirable and desirable [12].
In light of this, a logical step is to look at surrogate measures
of atherosclerosis.
Plasma lipoproteins
When transdermal HRT was first introduced it appeared to
be neutral in its effect on plasma lipoprotein metabolism [13],
which was consistent with avoidance of hepatic first-pass
metabolism. Larger and more sophisticated studies
confirmed the lack of effect on HDL levels, but showed
modest reductions in low-density lipoproteins and (less
consistently) lipoprotein(a), as well as an intriguing fall in
levels of fasting triglycerides [14]. When a progestin was
coadministered with transdermal HRT, HDL levels tended to
fall. Therefore, transdermal HRT theoretically has beneficial
effects on low-density lipoprotein (LDL), lipoprotein(a) and
triglycerides, but has little effect on HDL – a lipoprotein that
was previously considered the cornerstone of the
cardiovascular benefits of HRT.
Glucose and insulin homeostasis
Some studies suggest that oestrogens and progestogens
can induce a mild form of insulin resistance [15]. Because
insulin resistance may underlie many forms of CHD, claims
for a beneficial effect of transdermal HRT in this area of
Table 1
Differences in the cardiovascular risk profiles of oral and
transdermal HRT
Differences that favour 
transdermal or 
oral HRT Parameter
Transdermal Decrease in factor VII activity, fibrinogen, 
and triglycerides levels
Neutral effect on C-reactive protein
Oral Decrease in LDL and Lp(a) levels
Increase in HDL levels
Decrease in PAI-1 levels
Note that coadministration of progestin may influence many of these
changes. LDL, low-density lipoprotein.c
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cardiovascular risk were of obvious interest [16]. At present,
methodological arguments dominate this area of risk
assessment, but recent studies using the classic
‘euglycaemic clamp’ technique fail to show any influence of
transdermal HRT on insulin kinetics [17,18]. In this
procedure, plasma glucose levels are continually monitored
and kept stable or ‘clamped’ at a pre-agreed value, following
intravenous infusion of insulin. In contrast to insulin
resistance, an insulin-sensitive person needs more glucose to
maintain this plasma glucose level, because they respond
strongly to the insulin.
Coagulation and fibrinolysis
It was hoped that induction of a ‘prothrombic’ state linked
with oral HRT could be avoided with transdermal oestradiol,
because it has no effect on hepatic synthesis of coagulation
factors and other proteins that are involved in haemostasis.
The evidence for such a benefit is unconvincing, however.
Reductions in factor VII activity and fibrinogen levels have
been reported with transdermal therapy [19], which is
consistent with a reduction in plasma levels of triglyceride-
rich lipoproteins [20]. This potential benefit has to be
balanced against the claim that only oral oestrogen reduces
plasma levels of the inhibitor of fibrinolysis plasminogen
activator inhibitor (PAI)-1 [21]. This in turn has been
challenged by Falco et al [22], who claim that transdermal
oestradiol reduces PAI-1 levels and improves fibrinolysis in
CHD patients.
More comparative studies are needed, with an emphasis on
markers of haemostatic flux such as F1.2 and D-dimer.
Although transdermal HRT is often perceived to be free of the
increased risk for venous thromboembolism that is seen with
oral HRT, the evidence for such an assertion is weak [23].
Blood pressure
Transdermal oestradiol can reduce blood pressure [24] and,
in particular, restores the night-time blood pressure ‘dip’ that
is absent in some older individuals [25]. The clinical
significance of these small changes is uncertain, but raises
the possibility that transdermal HRT may be a better choice
for a subset of hypertensive women with genetic
susceptibility to oral oestrogen.
Vascular function
Despite claims that transdermal oestradiol has less effect on
plasma markers of endothelial function in comparison with
oral therapy [26], a recent study [27] found substantial
reductions in soluble intercellular adhesion molecule, E-
selectin and vascular cell adhesion molecule-1. The
disparities between studies may reflect the use of different
study populations, such as CHD patients or smokers. One
critical distinction between oral and transdermal HRT may
exist in the effect on plasma levels of C-reactive protein
(CRP), which is considered to be a marker of the
inflammatory response in atherosclerosis. Oral HRT
substantially increases plasma CRP levels, but this is not
seen with transdermal therapy [28,29].
de Ziegler et al [30] first showed that transdermal oestradiol
reduced vascular resistance in uterine arteries, and this was
subsequently confirmed in both coronary and carotid arteries.
Transdermal oestradiol improves forearm blood flow [31] and
coronary vasomotion [32], although studies of treadmill
performance in CHD patients are contradictory [33,34].
Despite some negative studies, there are sufficient clear
indications of a theoretical benefit with at least some
transdermal therapies in certain groups of women to
conclude that transdermal HRT has the potential to improve
arterial function. This is consistent with our understanding of
the direct actions of oestradiol on the arterial wall.
Conclusion
The severe mismatch between observed and expected
results for oral HRT in randomized controlled trials of CHD
end-points challenges the validity of observational
epidemiology, animal studies, and traditional CHD
surrogates. Transdermal HRT is considered inferior to oral
HRT for CHD prevention, because of the lack of effect on
HDL and PAI-1. If the apparent lack of activation of CRP by
transdermal HRT can be confirmed, and if the increased CRP
levels seen in oral HRT users can be linked to their adverse
clinical outcomes, then an adequately powered controlled
trial of transdermal HRT in the prevention of CHD would be
desirable. The lesson from recent HRT trials is that such a
venture should not be started in the absence of a consensus
regarding the study population (healthy women or CHD
patients) and regarding the use of progestin.
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